Cambridge Healthtech Institute's 27th International
Point-of-Care for Biodefense
June 18-19, 2019
The development of bioanalytical devices that are portable, compatible, scalable and reliable is critical to effective biodefense at the point-of-care. In addition, clinical data must be generated and incorporated into the key operational decision-maker
networks. Cambridge Healthtech’s 27th International Biodetection Technologies: Point-of-Care for Biodefense will bring together the global industry, academic and government biodefense community to discuss advancements in approaches for optimizing
performance of field technologies, translational challenges, regulatory approval of diagnostic tools, and data analysis to enable effective decision-making.
This event is in conjunction with our 27th International Biodetection Technologies: Biothreat and Pathogen Detection, as well as our 8th Annual Biosurveillance Integration conferences. Together, these events will provide three full days of programming
around biodetection technologies and biosurveillance in both the field and the lab.
Day 1 | Day 2 | Download Brochure
TUESDAY, JUNE 18
12:30 PM Registration
1:25 PM Chairperson’s Remarks
Harshi Mukundan, PhD, Team Leader, Chemistry Division, Los Alamos National Laboratory
1:30 An Affordable System for a Rapid Mass Casualty Response to a Large Area Coverage Biological Incident
Steven Hatfill, Adjunct Asstistant Professor, Microbiology & Immunology & Tropical Medicine, George Washington University
Based on the proven concept of the hospital trains used for mass casualty management during the first two World Wars, the concept for an all hazards “disaster train” is outlined to illustrate a new approach to consequence management of a large-scale
2:00 Facilitating the Path to Commercialization via Resources Provided by Centers for Point-of-Care Technology
PhD, Senior Scientist, Johns Hopkins Applied Physics Laboratory
Starting in 2007, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), established a network of centers to enhance the progression of promising technologies to the commercial market. The Johns Hopkins Center for Point of Care Tests
for Sexually Transmitted Diseases is one of those centers. It provides resources to industry and organizations at no charge to speed the progression of promising technologies to commercialization. These resources include technology comparisons, access
to physicians and other end users, de-identified clinical samples, implementation guidance, critical path funding and other resources to help companies reach the market faster.
2:30 How to Support Biodefense Policies with Solid Evidence-Based Fact? Lessons Learned from EU Policies that Required Solid Evidence-Based Facts
Van den Eede, Head of Unit, Knowledge for Health & Consumer Safety, European Commission
Any policy intervention/action/decision ought to be based on solid, evidence-based scientific facts that have been analysed with adequately validated reference methodologies. The presentation will provide examples on how this challenge is approached in
EU on other health-related EU policies, as a baseline of knowledge that might inspire the challenge on how to efficiently and globally coordinate efforts for biothreat and pathogen detection in support to biodefence policies.
3:00 Hospital Acquired Infections as a Threat to Public Health and Global Security
Peter Saama, Adjunct
Professor, Probability & Statistics, Michigan State University
The deliberate exploitation of naturally occurring infectious micro-organisms and release into vulnerable sub-populations constitutes a global catastrophic biological risk. Of specific concern is the intentional release of such organisms in a manner that
would elicit a burden of disease above and beyond the capabilities of available medical countermeasures. Consequences include increased morbidity, mortality, anxiety, societal instability, economic burden, and disruption of global security. Pediatric,
geriatric and immune-compromised patients are at a higher risk for hospital acquired infections (HAIs). We present and discuss risk factors for acute care neonatal, pediatric, and geriatric HAIs. This information is crucial for determining resource
needs for biothreat detection and mitigating risk which, in turn, strengthen preparedness.
3:30 Refreshment Break with Exhibit Hall with Poster Viewing
4:15 KEYNOTE PRESENTATION: Mass Applicable Vaccines against Highly Pathogenic Influenza Viruses
Juergen Richt, DVM, PhD, Regents Distinguished Professor & KBA Eminant Scholar, Director, Department of Homeland Security Center of Excellence
for Emerging and Zoonotic Animal Diseases, Kansas State University
Vaccination is one of the most effective ways to control influenza outbreaks and protect animal and public health. Newcastle disease virus (NDV)-based influenza vaccines have been demonstrated to be efficacious and safe in poultry. Herein, we developed
an NDV-based H5 vaccine (NDV-H5) that expresses a codon-optimized ectodomain of the hemagglutinin from an H5N2 virus and evaluated its efficacy in chickens. Results showed that both live and inactivated NDV-H5 vaccines completely protected chickens
from lethal challenge with a highly pathogenic H5N2 virus.
4:45 Anthrax Vaccine that Requires Only 3 Doses Compared to 6 Doses of Currently Licensed Anthrax Vaccine
Lallan Giri, PhD, CEO,
Biologics Resources LLC
Our newly developed anthrax vaccine has proven efficacious with only three doses of vaccine required for adults and children based on pre-clinical studies with approximately 3 doses over three months as compared to currently licensed anthrax vaccine which
requires 6 doses over 6 months.
5:15 End of Day & Dinner Short Course Registration*
6:00 Dinner Short Courses
SC1: Sample Preparation Technologies for Pathogen Detection
Instructor: Dave Alburty, CEO, InnovaPrep LLC
This tutorial will discuss sample preparation technologies for detection, identification and analysis of biomedical, biological and chemical agents, biothreats in point-of-care, laboratory and field settings. It will review the novel and rapid technologies
for sample preparation, application of analytical strategies and automation in biodetection.
* Separate registration required.
Day 1 | Day 2 | Download Brochure
WEDNESDAY, JUNE 19
8:30 AM Morning Coffee
8:55 Chairperson’s Remarks
Joany Jackman, PhD, Senior Scientist, Johns Hopkins Applied Physics Laboratory
9:00 A Single Diagnostic for Triage of Bacterial Infection - The Universal Bacterial Sensor
Mukundan, Principal Investigator & Team Leader, Chemistry for Biomedical Applications, Los Alamos National Laboratory
Extending the concepts of innate immune recognition to the laboratory can allow for universal diagnostics. We have been working on this premise for a decade, facing three major challenges - 1) detection on amphiphiles signatures, 2) sensitive diagnostic
platforms, and 3) engineering portable and automated systems. This presentation will cover a description of the development so far and clinical data demonstrating our sensor and approach.
9:30 A Smart Phone Platform for Detection of Zika Virus RNA in Low Resource Settings
Staff Scientist, Biotechnology & Bioengineering, Sandia National Labs
We present here a series of advances in portable nucleic acid amplification testing by interfacing our QUASR RT-LAMP assay detection with a consumer class smart phone that both controls simple assay hardware, and performs assay analysis and scoring. The
resulting system breaks conventional barriers of differential diagnostics by directly detecting multiple viral targets from crude human samples, including Zika, chikungunya, and dengue viruses, and providing proof of concept for a new generation of
fast, affordable, and portable diagnostic tools.
10:00 Networking Coffee Break
10:30 An RNA Detection Platform for Rapid Bacterial Identification and Combined Genotypic and Phenotypic Antibiotic Susceptibility Testing
Roby Bhattacharyya, PhD, Assistant in Medicine, MGH Division of Infectious Diseases; Instructor, Harvard Medical School; Researcher, Broad Institute of MIT and Harvard
In this talk we demonstrate that a multiplexed, hybridization-based RNA detection platform, NanoString, can be used for accurate and sensitive broad-range bacterial detection from crude lysates and primary clinical samples through rRNA detection, with
identification of known and phylogenetic classification of unknown organisms. We also show that transcriptional signatures of antibiotic response can be used for phenotypic antibiotic susceptibility testing (AST) on the same RNA detection platform,
with simultaneous measurement of key genetic resistance determinants in the same assay.
10:50 Point-of-Care Radiation Biodosimeter for Triage Following a Nuclear Event
Kathryn Todd, PhD,
Associate Laboratory Director, SRI International
The Biomedical Advanced Research and Development Authority (BARDA) has funded SRI International (SRI) under Contract HHSO100201700030C to develop a point-of-care (POC) radiation biodosimeter for use as a triage medical device in the case of a nuclear
event in an urban setting, where approximately 1M individuals may be exposed to ionizing radiation. This presentation will discuss the system concept, development, and validation strategy of SRI’s POC radiation biodosimeter. We will also address
the unique challenges of pursuing regulatory clearance for a POC triage radiation biodosimeter.
11:10 An Ultra-Fast, Simplified Sample-Prep Method for Tissue Samples: Integrated Sample Preparation and DNA Preservation Suitable for In-Field Use
Paul Reeves, Manager, Molecular Diagnostics Development, Arcis Biotechnology Ltd
11:30 Apolipoprotein H as a Sensor-Scavenger Protein Tool To Concentrate Pathogens For Their Early and Ultrasensitive Diagnostic To Improve Surveillance And/Or The Healthcare Mitigation
Francisco Veas, PhD, Professor, French Research Institute for Development (IRD); Head of the Comparative Molecular Immuno-Physiopathology Lab, French Ministry of Defense
Soon upon a homeostasis disruption of a given organism, due to trauma, autoimmune attack, or infection, the innate acute phase immune response is rapidly activated to restore the homeostatic profile. We have shown that ApoH is not only able to interact with multiple pathogens including enveloped or non-enveloped viruses and Gram-positive or -negative bacteria but also using ApoH-coated paramagnetic beads, we have developed methods to allow a very early and ultrasensitive detection (beyond the PCR limits) of multiple clinical or native blood-borne, water-borne air-borne, food-borne, nosocomial viruses and bacteria.
12:00 PM Enjoy Lunch on Your Own
1:40 Chairperson’s Remarks
Steven Hatfill, PhD, Adjunct Assistant Professor, Division of Clinical Research and Leadership, George Washington University School of Medicine
1:45 Same Day, Single Assay Identification of Seasonal and Emerging Influenza Viruses with FluChip-8G Insight
Amber Taylor, R&D Manager, Molecular Diagnostics, InDevR Inc.
FluChip-8G Insight is a microarray-based molecular assay that provides same day subtyping of seasonal and nonseasonal influenza A viruses and lineage differentiation of influenza B viruses in a single, multiplexed assay with automated data interpretation.
The FluChip-8G Insight assay is a powerful tool for influenza surveillance that provides same day identification of potentially pandemic influenza A while also providing detection and differentiation of seasonally circulating influenza viruses.
2:15 Physiological Models of the Most Potent Poison: Acute and Chronic Animal Models of Respiratory Botulism
McNutt, Principal Investigator, U.S. Army Medical Research Institute of Chemical Defense, USAMRICD
Botulinum neurotoxins (BoNTs) are a family of neuroparalytic proteins expressed by members of the Clostridium genus of anaerobic bacteria. Collectively, the BoNTs are the most poisonous substances known. Here we present new animal models to study
the progression and reversal of respiratory botulism with high resolution and use these models to demonstrate treatment strategies that effectively restore respiratory function in animals exposed to sublethal and lethal doses of botulism.
2:45 Networking Refreshment Break
3:00 A “Universal” Bio-Sample Stabilization & Preservation Medium: Simple, Low-Cost Environmental Sample Collection and Storage
Senior Technical Staff Member, Bioenergy & Biodefense Technologies, Sandia National Labs
We have discovered and continue to explore silica-based hybrid materials that have been successfully used for biomolecule and living cell stabilization. This sample stabilization medium addresses significant challenges faced by far-forward military
personal. Rapid in-field detectors can provide preliminary analysis of biosamples, but subsequent testing for validation or forensic analysis may be necessary. Safe and secure collection and stabilization of biological samples would allow
for accurate biosample identification, ensuring proper treatments are received. Further, allowing transport of biosamples from resource-limited regions to a modern bioanalytical laboratory would prove invaluable in identification of emerging/unknown
3:30 Bacterial Detection and Antimicrobial Resistance Testing Using Luminescent Bacteriophages: Clinical and Biodefense Applications
Christopher Hoefler, PhD, Computational Biologist, Draper
Draper has developed a diagnostic platform technology for rapid bacterial Identification and Antibiotic Susceptibility Testing (IDAST) utilizing engineered bacteriophage probes that produce light upon successful infection of a bacterial host.
To date, this “lumiphage” technology has targeted clinical applications, where rapid (<2 hours) identification of infecting agents and their antibiotic susceptibility profiles is urgently needed to combat the growing antimicrobial
resistance (AMR) problem. Approaches to bacterial diagnostic testing using bacteriophages will be discussed as well as a potential application for airborne bacterial threat detection.
4:00 Smartphone-Based Mobile Detection Platform for Rapid and Quantitative Molecular Diagnostics
Song, PhD, Research Assoc, Mechanical Engineering & Applied Mechanics, University of Pennsylvania
Rapid and quantitative molecular diagnostics in the field, at home, and at remote clinics is essential for evidence-based disease management, control, and prevention. Conventional molecular diagnostics requires extensive sample preparation, relatively
sophisticated instruments, and trained personnel, restricting its use to centralized laboratories. To overcome these limitations, we designed a simple, inexpensive, hand-held, smartphone-based mobile detection platform “smart-connected
cup”, for rapid, connected, and quantitative molecular diagnostics.
4:30 Close of Summit
Day 1 | Day 2 | Download Brochure